Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.
In this episode of Speaking of Urology®, Laura Bukavina, MD, MPH, and Kyle Rose, MD, discuss some of the notable abstracts that were presented at the American Society of Clinical Oncology (ASCO) Gastrourinary (GU) Cancers Symposium, which was held January 16-18, 2023 in San Francisco, California. Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Rose is a urologic oncology fellow at Moffitt Cancer Center in Tampa, Florida.
This recap was originally presented by Dr. Bukavina and Dr. Rose during the inaugural live Twitter Spaces event held by Urology Times. In the discussion, Bukavina and Rose touched on the following abstracts:
Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.